Immunome (IMNM) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Vision and strategy

• Focused on improving cancer patient outcomes using antibody-drug conjugates (ADCs) and opportunistically adding targeted therapies when impactful.

• Emphasizes flexibility in adopting new modalities to address unmet needs in oncology.

AL102 program and clinical progress

• Licensed AL102, a gamma-secretase inhibitor, due to its strong chemistry, high potency, and promising phase II data across multiple dosing regimens.

• Phase II data showed objective response rates in the mid-60s and deep tumor regression, outperforming benchmarks.

• Phase III trial for AL102 in desmoid tumors is fully enrolled, with top-line data expected in the second half of 2025.

• Plans to commercialize AL102 globally, leveraging a new head of commercial with extensive launch experience.

Market opportunity and commercialization

• Desmoid tumor prevalence in the US is over 30,000, with 6,000–7,000 treated annually and 1,600 new cases per year; similar numbers in Europe.

• Once-daily dosing and superior efficacy could drive adoption, especially for new and non-responsive patients.

• Global rights to AL102 enable direct launches in major markets and distributor partnerships elsewhere.